Trial description:
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)
Contact name:
Dr Gary Doherty
Trial start date:
Friday, September 18, 2020
Trial end date:
Monday, September 30, 2024
Trial tumour type:
Lung
Show on Radiotherapy:
No
